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The human immunodeficiency virus type 1 (HIV-I) genome codes for trans-activator Tat, an 86-residue protein whose expression is critical for 
viral replication. Full-length Tat and Tat peptides from HIV-l were chemically synthesized using optimized solid phase technique. Synthetic Tat? 86 
was found not only to inhibit antigen-induced human peripheral blood lymphocyte (PBL) proliferation in vitro, as described by Viscidi et al. 11989, 
Science 246, 16061608], but also mitogen-induced PBL proliferation, with 50% inhibition obtained at 0.9 and 8 PM, respectively. To assess the 
mechanism by which Tut exert its inhibitory effect, we analysed its interaction and effect on CD4+-cells. Direct fluorescence and indirect 
immunofluores~~ assays analysed by flow cytometry showed that fluorescein isothiocyanate-laxly and -unlabeled Tat interact (20.2pM) with 
CD,-expressing I~p~oid cells (CEM cell line). Experiments of chromium-5 1 release and Trypan blue exclusion on these tumor cells in vitro have 
demonstrated the capacity of Tat to modify cellular membrane permeability and cell viability, in a dose-dependent manner. The use of Tat peptides 
revealed that those containing the Tat basic region from 49 to 57 were able to bind to the cell membrane and to exhibit a cytotoxic activity on 
lymphocytes. Together, the data suggest hat the potential cytotoxicity of Taf on lymphocytes could be directly implicated in virus-induced immune 
dysfunction observed in HIV-l infected patients. 
HIV; Tar; Cytotoxicity; Lymphocyte; Synthetic peptide 
1. INTRODUCTION 
The human immunodeficiency virus type 1 (HIV-l) 
genome codes for a potent trans-activator protein of 86 
amino acid residues, termed Tat (Fig. l), which expres- 
sion is required for viral replication [l-5]. Tat interacts 
with a c&acting element (TAR) mapped in the R region 
of the long terminal repeat (LTR) and dramatically in- 
creases the steady-state levels of viral messenger RNAs 
[68]. Complex action of Tat was previously reported 
on levels of transcription initiation [7,9,10], anti-attenu- 
ation [ 111, translational efficiency [ 121, or a combination 
thereof [13]. This regulatory protein factor seems to be 
released in a biologically active form in the supernatant 
of HIV-l-infected cells in vitro 1141. Structure-acti~ty 
relationships studies using synthetic peptides and site- 
directed mutagenesis clearly show the existence of sev- 
eral functional domains and importance of the cysteine- 
and basic residue-rich regions for Tat nuclear location 
and trans-activating function [15-231. In parallel to 
trans-activation, it has been reported some other novel 
potential molecule activities such as induction and de- 
velopment of Kaposi’s sarcoma 114,241 and immuno- 
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suppression [25]. In the later case, the recombinant pro- 
tein seems to selectively inhibit, in a dose-dependent 
manner, antigen-induced lymphocyte proliferation (tet- 
anus toxoid, candida antigens) while no significant in- 
hibitory effect of Tat on cellular proliferation was ob- 
served after mitogenic stimulation (phytohemagglutinin 
P (PHA), pokeweed mitogen). We have previously 
shown 1261 that synthetic Tat can act on the central 
nervous system. This activity corresponds to an interac- 
tion and cytotoxic effect of Tut on neural cell lines in 
vitro, as well as a neurotoxicity lethal in mice in vivo. 
The use of Tat peptide derivatives allowed to determine 
that the conserved basic region 49-57 of Tat was neces- 
sary and sufficient for cell membrane binding and neu- 
rotoxicity. In order to investigate the cellular specificity 
of Tat toxicity and the potential molecule implication 
in immune dysfunction, we measured the effect of ex- 
ogenous protein on CD,‘-lymphoid cells (CEM cell 
line) and on human peripheral blood lymphocyte prolif- 
eration in vitro. 
2. MATERIALS AND METHODS 
2.1. Pepride synthesis 
Chemical synthesis of Tut2.,, and Tat peptides was performed by 
the solid-phase method [27,28]. Stepwise elongation of the peptide 
chains was carried out automatically (synthesizer model 430 A, Ap- 
plied Biosystems, Foster City, CA) on 4-(oxymethyl)-phenylacet- 
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Fig. 1. Predicted amino acid sequence of HIV-l Tut protein (]Lai isolate). 
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polystyrene resin mmol) using optimized t-buty- 
loxycarbonyi (Boc)/benzyl chemistry, as described f29f. 
Cells of the CEM line, clone 13 {American Type Culture Collection, 
Rockville, MD), were cultured at 37°C in RPM1 1640 medium (Flow 
Laboratories Inc., Irvine, Scotland) supplemented wtth 10% fetal calf 
serum, 1% glutamme, and 1% streptomycin-penicillin antibiotics 
(Gibco Laboratories. Parsley, Scotland) in a humidified atmosphere 
with 5% CO?. 
Peripheral blood l~phocytes fPBL) from four healthy HIV-K se- 
ronegative donors were rsolated from heparinlzed blood by the Ficoll- 
Hypaque technique. Culture medium was RPM1 1640 supplemented 
with I % glutamine, 1% antibiotics and 10% heat inacttvated fetal calf 
serum. Cells (10”) in 200 ~1 final volume were incubated m mtcrotitre 
plate wells in the presence of various concentrations of Tutz~sh (0.18 
to 35 PM), or Tar peptide derivatives (0.5 to 6OyM). with or without 
tuberculin antigen (PPD; 12.5 &ml) or mitogens (T-cell specific 
phytohema~~utinin P (PHA), B-cell specific pokcweed mitogen). On 
day 6, cuhures were pulsed for 8 h with 1 pCi of [~H]th~Imidine 
(Amersham Int., Amersham, UK). Celts were harvested and [-‘H]thy- 
midine incorporation into DNA was counted in a beta counter {Pack- 
ard, Downers Grove, IL). 
2.4 CEM und PBL ceN blnding of s_vnthetic Tat z 8o und Tat peptide 
Cell binding of varying amounts of synthetic Tat 2 86 or Tar peptides 
was assessed by either direct fluorescence assay using FITC-labeled 
Tar z 86 or by indirect immunofluorescen~ assay, as described prevr- 
ously [26]. 
CEM cells (2~10~ cells/ml) were radiolabeled for 12 h at 37°C with 
100 ,Ki chromium-51 sodmm chromate (Amersham Inc., Chicago, 
IL) in RPM1 1640 containing 1% fetal calf serum. Labeled cells were 
washed and suspended in medium at lo6 cells/ml and dispensed m 100 
,& aliquots into a flat-bottomed 96-well microtitre plate (Cormng, 
Corning. NY). Various amounts of ‘Fu~~.~~ (0.18-18 PM) and I?& 
peptide dertvatives (0.2-60 yMf were added to each well. After 4 h 
mcubation at 37°C in 5% CQ humid&d atmosphere, cell-free super- 
natants were harvested and counted m a gamma counter (Koritron, 
Zurich. Switzerland). Weils containing labeled cells in RPMI alone or 
in RPM1 plus 1% (v/v) Triton X-100 served as controls for spontane- 
ous and maximal cellular 5’Cr release, respectively. 
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Viability of CE~ or PBL cells [I@) previously incubated (1 h, 37’C) 
with 50 ~1 solutions of Tag z 8* @.O7-35 gg; 0.1470 PM) was moni- 
tored by using Trypan blue staining. 
3. RESULTS 
inhibit antigen-induced, but not mitogen-induced, 
human peripheral blood mononuclear cell (PBL) prolif- 
eration [25]. In order to confirm these data and to deter- 
mine the region responsible for this inhibitory effect, we 
investigated the effect of synthetic Tat 2_86 and Tat pep- 
tide derivatives on human PBL proliferation. Stimula- 
tion of P3L (l@) with PPD antigen in the presence of 
increased amounts of Tat 2_86 (0.18-8.8 PM), or Tczt 
peptides (3.2 to 32 ,uM), resulted in a dose-dependent 
inhibition of PPD-induced lymphocyte proliferation 
(Fig. 2A). Under our experimental conditions, 50% in- 
hibition was obtained with a concentration of Tat,,,of 
0.9,uM. Peptides Tat,,_,, and Tat 38_72 also inhibited 50 
and 58% of PBL proliferation at concentrations of 2.3 
and 3.2 PM, respectively. The effect of T&,, and Tat 
peptides on mitogen-induced l~pho~te proliferation 
was further investigated using phytohemagglutinin P
(PHA; 1:400) and pokeweed mitogens on PBL samples 
from four HIV-l seronegative donors. From the four 
PBL samples tested, Tat,_,, inhibited 10, 30, 50 and 
100% of lymphocyte proliferation at concentrations of 
about 0.35, 3.5, 8 and 20 PM, respectively (data not 
shown). The capacity of various Tat peptides to inhibit 
PHA-induced lymphocyte proliferation is illustrated in 
Fig. 2B. The results show that peptides Tat2,_86, Tat 21_R(i 
CM (carboxymethylcysteine derivative), Tat,,,, and 
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Fig. 2. (A) Inhibition of tuberculin antigen (PPD)-induced human peripheral blood lymphocyte (PBL) proliferation in vitro by Tut 246 and Tat 
peptides. (B) Inhibition of PHA-induced lymphocyte (PBL) proliferation in vitro by Tuc~_~~ and Tar peptides Percent inhibition of the PPD- and 
PHA-induced lymphocyte (PBL) proliferation in vitro was calculated as: lOO-[(cpm,,,,,,,,,,,-cpm,,,,,,)/(cpm mar,ma,-cpmcontro,)xlOO]. Spontaneous 
(cpm con,ro,) and maximal (cpm maxima,) PBL proliferations were determined, respectively, in culture medium alone and in medium plus PPD (A), 
or PHA (B). Spontaneous and maximal PBL proliferations were, respectively, at about 200 and 2,600 cpm (PPD stimulation), 500 and 27,000 cpm 
(PHA stimulation). The standard deviation (S.D.) of samples was always ~10% of the mean. Data are mean counts per minute (cpm) + 1 S.D. 
of quadruplicate replicates. Experimental conditions are described in Section 2. 
Tat 38-72, which contain the entire basic domain, fully 
inhibited the PHA-induced proliferative response. 
These Tat peptides induced about 10, 50 and 100% 
inhibition at concentrations ranging from 2 to 5, 10 to 
20, and 20 to 50 ,uM, respectively. In contrast, Tat,-,, 
and Tat,,-,,, or basic fragment l-34 of human spleen 
Hlb histone, had negligible inhibitory effect at mM 
concentration. 
To investigate the mechanism by which Tat exert its 
immunosuppressive activity, we analysed both the inter- 
action of synthetic Tat and Tat peptides with lymphoid 
cells and their effects on cell permeability and viability. 
3.2, Interaction of synthetic Tat,,, with CD,‘-CEM cell 
line and PBL cells 
Flow cytometry analysis of CEM cells (106) previ- 
ously incubated with increased concentrations of FITC- 
labeled Tat 2m86 (0.2-20 PM) shows the capacity of la- 
beled Tat,_,, to interact with cells below its ,uM concen- 
tration (>0.2pM), in a dose-dependent manner (Fig. 3). 
The cell fluorescence could be associated with intracel- 
lular labeling due to cellular uptake of FITC-labeled 
Tat,,, and/or with surface labeling of the cell mem- 
brane. This interaction was further analysed by indirect 
immunofluorescence assay. In agreement with direct 
binding assay, results obtained shows the dose-depend- 
ent Tat-cell surface membrane binding stained by rabbit 
anti-Tat antibodies (data not shown). FITC-labeled or 
-unlabeled Tat peptides were used, respectively, in direct 
(Fig. 4) or indirect (data not shown) binding experi- 
ments to delineate the Tat site of binding to the cell 
membrane. Results show that Tat peptides (>5 PM) 
which include the basic domain 49-57 (Tat 3840 and 
Tat,,-,,) bound to CEM cells while Tat 2_23 and Tat,,_,, 
at about lo-fold higher concentrations were not signifi- 
cantly active for binding. A similar specific binding of 
Tat was obtained when incubation was done with 
human PBL (data not shown). 
3.3. Effect of synthetic Tatzq6 on the CD,+-CEM cell 
membrane permeability and cell viability 
Post-binding effect of Tat,-,, on cell membrane per- 
meability was investigated by “Cr release assay from 
Tat,-,,- treated labeled CEM cells. Incubation (4 h, 
37°C) of chromium-51 labeled cells ( 105) with increased 
amounts of Tat 2&O. 1 ~-PM) clearly shows the protein 
effect on cell permeability (Fig. 5A,B). A significant 
cellular 5’Cr release was observed below PM concentra- 
tion of Tatz_86 (0.2 to 1 PM) and 66% “Cr release was 
obtained at 18 PM. The synthetic Tat peptides that 
contain the Tat basic domain (Tat,,_,,, Tat 3&60, Tat,,-,, 
and Tatj8& produced similar effect on these cells (Fig. 
5A,B). Tat,,-,,(24 ,uM) and Tat,,&23 PM) induced 70 
and 90% 5’Cr release, respectively (Fig. 5A). Peptides 
Tat,-,, (60 PM) and Tat 57&52pM) did not elicit signif- 
icant “Cr release from labeled cells (Fig. 5B), as well as 
highly basic control fragment l-34 of human spleen 
Hlb histone [30] at similar concentration (Fig. 5A,B). 
The effect of Tat on cell viability was also investigated 
by Trypan blue exclusion of CEM cells or human PBL 
treated with Tat (0.1-100 mM). Results (Fig. 6) clearly 
showed the cytotoxicity of Tat with about 40% of cell 
death at 10 mM Tat concentration. 
4. DISCUSSION 
It was reported that Tat protein selectively inhibits 
antigen-induced, but not mitogen-induced, lymphocyte 
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Fig. 5. (A,B) Effect of synthetic Tut, 86 and Tat peptides on chromium-5 1 release from labeled CEM cells. Tut?_,, (0.18-I 8 ,uM) and Tar peptides 
(0.2-6OpM) were incubated with chromated CEM cells (5~10~). Chromated cells in culture medium alone or in medium plus 1% (v/v) Triton X-100 
served as controls for spontaneous (~2,000 cpm) and maximal (13,000 cpm) cellular “Cr release, respectively. The highly basic fragment l-34 from 
human spleen Hlb histone was used as negative control. Percent chromium-51 release from labeled cells was calculated as: (cpm,,penmen,a,-cpm~~“,~~,)/ 
(cpm max,ma,-cpmcon,ro,)xlOO. The standard deviation (S.D.) of samples was always ~10% of the mean. Data are mean counts per mmute (cpm) !I 
1 S.D. of duplicate quadruplicates. Experimental conditions are described in Section 2. 
ment l-34 Hlb histone, were found inactive. These re- 
sults are consistent with the capacity of Tar and Tut 
peptides including the basic domain to interact with cell 
membrane and to modify cell permeability. We have 
shown by direct and indirect binding assays the capacity 
of Tut to bind to cell membranes via its basic domain 
which is highly conserved among various HIV-l iso- 
lates. This region (2 lysines and 6 arginines within 9 
residues) was previously found to be critical for efficient 
Tut trans-activation and was presumed to be a nuclear 
targeting signal or a nucleic acid binding site [16,17,21- 
23, 311. Post-binding effect of Tat and Tat peptides on 
CEM cell membrane permeability was investigated by 
“Cr release assay of chromium-51 labeled CEM cells. 
The results obtained have shown that Tut 2m86 modifies 
cell membrane permeability below ,uM concentration 
(0.2-l ,uM), in a dose-dependent manner, with 66% “Cr 
release obtained at 18 ,uM of Tat 2m86. A dose-dependent 
and specific “Cr release from labeled CEM cells was 
also observed with Tut peptides which contained the 
basic domain 49-57 (Tat 2,_86r Tat,,,, TatJsm,, and Tat 
38_86). while Tat,_,, and Tat,,,6, or highly basic fragment 
l-34 from human spleen Hl b histone [30], were inactive 
for cellular “Cr release. Binding and “Cr release assays 
using Tut peptides suggest that the basic domain of 
Tat,-,, could be involved in both the interaction and 
permeabilization of the CEM cell membranes. These 
results suggest hat Tat- mediated inhibition of the mi- 
togen-induced lymphocyte proliferation could be di- 
rectly caused by a cytolytic activity of the protein via its 
basic domain. 
The biological effects are occasionally observed in 
vitro at relatively high Tatzm,, concentration (0.2 to 10 
PM), although there is no evidence for free Tat,_86 at 
such a concentration in the plasma of HIV-infected in- 
dividuals. Nevertheless, it has been reported that Tat 
binds to several cell type at micromolar concentrations 
and enters these cells by endocytosis [32]. Also, it cannot 
be ruled out that the high concentration of the protein 
could be attainable locally within some acutely replicat- 
ing-HIV cells. In addition, Tut,m,, could act synergisti- 
cally with other viral and/or cellular factors, as it has 
100 
- PBL 
e. _ - CEM 
-7 -6 -5 -4 
Log [Tat1 (W 
Fig. 6. Dosedependent effect of synthetic Tut 2_86 on CEM and PBL 
cell viability. Viability of CEM cells and human PBL (106) preincu- 
bated (1 h, 37°C) in the absence or in the presence of varying concen- 
trations of synthetic Tut2 86. The cell viability was monitored by Try- 
pan blue staining. 
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been shown recently for Tat trans-activation [33-3.51, to 
bring about increased cell lysis. Such synergistic cyto- 
toxicity has previously been described for human neu- 
trophil defensin, a highly basic peptide exhibiting cy- 
tolytic activity at concentrations of l-50pM [36]. Many 
basic cytotoxic proteins and peptides, implicated in con- 
tact dependent antibody-mediated cytotoxicity and an- 
timicrobial activity [3741], are active at the micromolar 
concentration. The common mechanism by which all 
these basic peptides damage target cell membrane is 
reported to be the pore formation, leading to non-ion- 
selective membrane permeability, Tat 246 may belong to 
this class of cationic proteins. 
In summary, our results show that Tat 2_86 and its 
peptide derivatives containing Tat basic domain are 
able (i) to bind to CEM and PBL cells. (ii) to modify cell 
membrane permeability and viability of these cells, and 
(iii) to inhibit both antigen- and mitogen-induced 
human lymphocyte (PBL) proliferation in vitro. 
Taken together, the results may suggest hat Tat 2_86r 
by acting on the immune system, could be directly in- 
volved in the immune dysfunction associated with HIV 
infection. Thus, the specific inhibition of the Tat 2_86ac- 
tivity could be an effective therapeutic approach to the 
treatment of AIDS. 
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